Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Cash from Operations (2016 - 2025)

Cytosorbents (CTSO) has disclosed Cash from Operations for 14 consecutive years, with 2577000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations fell 4.63% year-over-year to 2577000.0, compared with a TTM value of 9892809.0 through Sep 2025, up 46.51%, and an annual FY2024 reading of 14427809.0, up 33.37% over the prior year.
  • Cash from Operations was 2577000.0 for Q3 2025 at Cytosorbents, down from 1510045.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 1510045.0 in Q2 2025 and bottomed at 8119170.0 in Q1 2022.
  • Average Cash from Operations over 5 years is 4519727.68, with a median of 4794241.0 recorded in 2024.
  • The sharpest move saw Cash from Operations crashed 419.15% in 2021, then surged 68.5% in 2025.
  • Year by year, Cash from Operations stood at 5491599.0 in 2021, then grew by 2.75% to 5340327.0 in 2022, then fell by 19.98% to 6407411.0 in 2023, then surged by 63.47% to 2340809.0 in 2024, then decreased by 10.09% to 2577000.0 in 2025.
  • Business Quant data shows Cash from Operations for CTSO at 2577000.0 in Q3 2025, 1510045.0 in Q2 2025, and 3464955.0 in Q1 2025.